Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial

Probert, C S J, Hearing, S D, Schreiber, S, Kühbacher, T, Ghosh, S, Arnott, I D R and Forbes, A ORCID: https://orcid.org/0000-0001-7416-9843 (2003) Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut, 52 (7). pp. 998-1002. ISSN 0017-5749

Full text not available from this repository. (Request a copy)

Abstract

Tumour necrosis factor production is increased in the mucosa of patients with active ulcerative colitis. The benefits of infliximab in Crohn's disease are established. We investigated its efficacy in ulcerative colitis.

Item Type:	Article
Uncontrolled Keywords:	adult,anti-inflammatory agents,antibodies, monoclonal,c-reactive protein,colitis, ulcerative,double-blind method,drug resistance,female,glucocorticoids,humans,immunosuppressive agents,male,middle aged,quality of life,remission induction,treatment outcome
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology Faculty of Medicine and Health Sciences > Research Groups > Nutrition and Preventive Medicine
Depositing User:	Pure Connector
Date Deposited:	06 Aug 2014 10:56
Last Modified:	20 Oct 2022 23:59
URI:	https://ueaeprints.uea.ac.uk/id/eprint/49585
DOI:	10.1136/gut.52.7.998

Actions (login required)

View Item